Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Wong Deborah JL"'
Autor:
von Euw Erika, Atefi Mohammad, Attar Narsis, Chu Connie, Zachariah Sybil, Burgess Barry L, Mok Stephen, Ng Charles, Wong Deborah JL, Chmielowski Bartosz, Lichter David I, Koya Richard C, McCannel Tara A, Izmailova Elena, Ribas Antoni
Publikováno v:
Molecular Cancer, Vol 11, Iss 1, p 22 (2012)
Abstract Background TAK733 is a novel allosteric, non-ATP-binding, inhibitor of the BRAF substrates MEK-1/2. Methods The growth inhibitory effects of TAK733 were assessed in a panel of 27 cutaneous and five uveal melanoma cell lines genotyped for dri
Externí odkaz:
https://doaj.org/article/ce5029448ceb46ae8246771e3b3ee94f
Autor:
Wong, Deborah JL, Hurvitz, Sara A
Publikováno v:
Annals of translational medicine, vol 2, iss 12
Human epidermal growth factor receptor 2 (HER2)-targeted therapies have revolutionized the treatment of HER2-positive breast cancer, both in the metastatic and early stage settings. While trastuzumab and lapatinib had been the mainstays of treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______325::868926e3359ea5a25b51f6585812eade
https://escholarship.org/uc/item/5n73n00m
https://escholarship.org/uc/item/5n73n00m
Autor:
Wong, Deborah JL, Robert, Lidia, Atefi, Mohammad S, Lassen, Amanda, Avarappatt, Geetha, Cerniglia, Michael, Avramis, Earl, Tsoi, Jennifer, Foulad, David, Graeber, Thomas G, Comin-Anduix, Begonya, Samatar, Ahmed, Lo, Roger S, Ribas, Antoni
Publikováno v:
Molecular cancer, vol 13, iss 1
BackgroundIn melanoma, dysregulation of the MAPK pathway, usually via BRAF(V600) or NRAS(Q61) somatic mutations, leads to constitutive ERK signaling. While BRAF inhibitors are initially effective for BRAF-mutant melanoma, no FDA-approved targeted the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::ab984d3c9dfc77a367ca071ac6a557e0
https://escholarship.org/uc/item/9wp4z6w3
https://escholarship.org/uc/item/9wp4z6w3
Autor:
Wong, Deborah JL1 (AUTHOR), Robert, Lidia1,2 (AUTHOR), Atefi, Mohammad S1 (AUTHOR), Lassen, Amanda1 (AUTHOR), Avarappatt, Geetha1,3 (AUTHOR), Cerniglia, Michael1 (AUTHOR), Avramis, Earl1 (AUTHOR), Tsoi, Jennifer4 (AUTHOR), Foulad, David1 (AUTHOR), Graeber, Thomas G4 (AUTHOR), Comin-Anduix, Begonya5,6 (AUTHOR), Samatar, Ahmed7 (AUTHOR), Lo, Roger S4,6,8 (AUTHOR), Ribas, Antoni1,4,5,6 (AUTHOR) aribas@mednet.ucla.edu
Publikováno v:
Molecular Cancer. 2015, Vol. 14 Issue 1, p128-128. 1p.
Autor:
Lassen A, Atefi M, Robert L, Wong DJ, Cerniglia M, Comin-Anduix B, Ribas A; Department of Medicine, Division of Hematology-Oncology, David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA. aribas@mednet.ucla.edu.
Publikováno v:
Molecular cancer [Mol Cancer] 2014 Apr 16; Vol. 13, pp. 83. Date of Electronic Publication: 2014 Apr 16.